Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
E Clair McClung, Robert M WenhamDepartment of Gynecologic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USAAbstract: Patients with platinum-resistant ovarian cancer have progression of disease within 6 months of completing platinum-based chemotherapy. While several chemotherapeutic opt...
Main Authors: | McClung EC, Wenham RM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-03-01
|
Series: | International Journal of Women's Health |
Subjects: | |
Online Access: | https://www.dovepress.com/profile-of-bevacizumab-in-the-treatment-of-platinum-resistant-ovarian--peer-reviewed-article-IJWH |
Similar Items
-
Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014-07-01) -
Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
by: Michele Bartoletti, et al.
Published: (2020-05-01) -
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
by: Tadahiro Shoji, et al.
Published: (2018-07-01) -
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
by: Eva María Guerra Alía, et al.
Published: (2019-06-01) -
A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
by: Cui Q, et al.
Published: (2021-01-01)